Taylor & Francis Group
iett_a_1075509_sm5863.doc (192 kB)

Tricetin suppresses the migration/invasion of human glioblastoma multiforme cells by inhibiting matrix metalloproteinase-2 through modulation of the expression and transcriptional activity of specificity protein 1

Download (0 kB)
Version 3 2015-10-08, 13:56
Version 2 2015-10-08, 13:56
Version 1 2015-10-03, 00:00
journal contribution
posted on 2015-10-08, 13:56 authored by Rockey Chao, Jyh-Ming Chow, Yi-Hsien Hsieh, Chi-Kuan Chen, Wei-Jiunn Lee, Feng-Koo Hsieh, Nuo-Yi Yu, Ming-Chih Chou, Chao-Wen Cheng, Shun-Fa Yang, Ming-Hsien Chien

Objective: Glioblastoma multiforme (GBM) is a severely invasive tumor that can be fatal because it is difficult to treat. Tricetin, a natural flavonoid, was demonstrated to inhibit the growth of various cancers, but the effect of tricetin on cancer motility is largely unknown.

Research design and methods: In the present study, we examined the anti-invasive properties of tricetin in huwman GBM cells.

Results: Our results showed that tricetin inhibited the migration/invasion of two GBM cell lines. We found that tricetin inhibited MMP-2 expression in the GBM cells. Real-time polymerase chain reaction and promoter activity assays indicated that tricetin inhibited MMP-2 expression at the transcriptional level. Such inhibitory effects were associated with the suppression of specificity protein-1 (SP-1) DNA-binding activity. An examination of clinical samples revealed a positive correlation between SP-1 and MMP-2 in glioma specimens, and higher expression levels were correlated with a worse probability of survival. Moreover, blocking the extracellular signal-regulated kinase (ERK) pathway also inhibited MMP-2-mediated cell motility, and further enhanced the anti-invasive ability of tricetin in GBM cells.

Conclusions: SP-1 is an important target of tricetin for suppressing MMP-2-mediated cell motility in GBM cells, and a combination of tricetin and an ERK inhibitor may be a good strategy for preventing GBM invasion.